Please login to the form below
fitusiran
This page shows the latest fitusiran news and features for those working in and with pharma, biotech and healthcare.
Roche’s Hemlibra scores broader NHS funding
Competition is heating up in haemophilia, however. Alnylam's late-stage candidate fitusiran is tipped as a major competitor to Hemlibra, while the first gene therapies are also on the horizon.
Latest news
-
ACPs to lead gene therapies in haemophilia market growth
New therapies to hit existing players. Roche’s Hemlibra and Alnylam’s late-stage candidate fitusiran are likely to seize a bigger share of an expanded haemophilia market than gene therapies, ... The two drugs have distinct mechanisms – Hemlibra
-
Sanofi exits R&D pact with Alnylam on rare disease
The R&D deal was tweaked in January last year, with Sanofi licensing an RNAi drug called fitusiran for haemophilia A and B as well as other rare bleeding disorders, but ... Prospects for haemophilia candidate fitusiran looked a little shaky in 2017 when
-
FDA lifts clinical hold on Sanofi’s haemophilia drug
Fitusiran holds the potential to help improve the lives of people living with haemophilia,” said Akin Akinc, who is leading the development of the drug at Alnylam. ... With the additional risk mitigation measures in place, we look forward to the
-
Alnylam takes off on APOLLO trial results
Safety is an important finding as patient deaths have affected some of the firm's other programmes, including most recently haemophilia candidate fitusiran which had a trial halted as a result,
-
Solid start for Dupixent as Sanofi raises 2017 outlook
PD-1 in multiple cancer indications and fitusiran in haemophilia were significant R&D milestones in the second quarter".
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
instead taking a lead marketing role for their co- developed haemophilia candidate fitusiran. ... Alnylam has three more RNAi medicines in its late stage pipeline: Fitusiran in haemophilia, being co-developed with Sanofi; inclisiran for
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Director – UK Office
-
Excellent salary and benefits
Subscribe to our email news alerts
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Moving annual total (MAT)
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Leaked no-deal Brexit document forecasts widespread shortages
- FDA rejects Sarepta’s new Duchenne drug over safety fears
- Novo Nordisk shareholder revolt reaches Europe
PMHub
GCI Health
GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
